APVO
Aptevo Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
APVO Profile
Aptevo Therapeutics Inc.
A biotechnology company developing novel immunotherapies for cancer and autoimmune diseases
Biological Technology
Invalid Date
08/01/2016
NASDAQ Stock Exchange
37
12-31
Common stock
2401 4th Avenue, Suite 1050, Seattle, Washington 98121
--
Aptevo Therapeutics Inc., was incorporated in Delaware in February 2016. The company is a clinical-stage R&D biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. The company has developed two multi-functional platform technologies for the rational design of precision immunomodulatory drugs. The Company's main clinical candidates APVO436 and ALG.APV-527 and preclinical candidates APVO603 and APVO711 were developed using the ADAPTIR modular protein technology platform. The company's preclinical drug candidate APVO 442 was developed using the ADAPTIR-FLEX modular protein technology platform. The company's ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific and multispecific candidate antibodies that enhance the human immune system against cancer cells.